EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma

Philippe Bareille iD, Varsha Imber iD, Jodie Crawford, Bernadetta Majorek-Olechowska, Zeina Karam-Absi, Sally Stone, Ruby Birk

Pediatric Pulmonology · 2023

DOI: 10.1002/ppul.26679 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Pulmonology, 2023. Verfasst von Philippe Bareille und 6 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Stevenage, UK. Hauptthemen laut MEDLINE: Bronchodilator Agents, Asthma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction : Growth impairment is a known adverse event (AE) of corticosteroids in children. This study aimed to assess the effect of once‐daily (QD) inhaled fluticasone furoate (FF) versus placebo on growth velocity over 1 year in prepubertal children with well‐controlled asthma. Materials and Methods : This randomized, double‐blind, parallel‐group, placebo‐controlled, multicenter study (NCT02889809) included prepubertal children, aged 5 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchodilator AgentsAsthmaFemaleHumansChildMaleAdministration, InhalationDouble-Blind MethodTreatment OutcomeFluticasoneAcetatesCyclopropanesQuinolinesSulfidesAndrostadienes

Stichwörter der Autor:innen

heightinhaled corticosteroidspediatric asthma

Substanzen

Bronchodilator AgentsFluticasonemontelukastAcetatesCyclopropanesQuinolinesSulfidesfluticasone furoateAndrostadienes

Autor:innen und Institutionen

  • GSK, Stevenage, UK.
  • GSK, Brentford, London, UK.
  • Alergo-Med Specialist Medical Clinic, Tarnów, Poland.
  • Parexel International, Paris, France.

ORCID-Profile: Philippe Bareille, Varsha Imber

Förderung

  • GSK

Zitieren

APA

Bareille, P., Imber, V., Crawford, J., Majorek-Olechowska, B., Karam-Absi, Z., Stone, S., & Birk, R. (2023). A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26679

Vancouver

Bareille P, Imber V, Crawford J, Majorek-Olechowska B, Karam-Absi Z, Stone S, et al. A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma. Pediatric Pulmonology. 2023. doi:10.1002/ppul.26679

BibTeX
@article{Bareille2023,
  author = {Bareille, Philippe and Imber, Varsha and Crawford, Jodie and Majorek-Olechowska, Bernadetta and Karam-Absi, Zeina and Stone, Sally and Birk, Ruby},
  title = {A multicenter randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate the effects of a 1‐year regimen of orally inhaled fluticasone furoate 50 µg once daily on growth velocity in prepubertal, pediatric participants with well‐controlled asthma},
  journal = {Pediatric Pulmonology},
  year = {2023},
  doi = {10.1002/ppul.26679}
}
Kostenlos starten →